Business Context and Reporting Period
Kura Oncology, Inc. (KURA) filed a Form 8-K on November 4, 2021, to announce financial results for the third quarter ended September 30, 2021, and to provide a corporate update. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It serves as a notification that the third-quarter results and corporate update have been issued.
Guidance, Outlook, and Risks
The filing references a corporate update and press release (Exhibit 99.1) for management commentary, outlook, and risk factors. The text explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, limiting liability and incorporation by reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 4, 2021) for specific Q3 2021 financial figures.
- Verify the company's cash position and burn rate in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the corporate update.
- Confirm the status of any debt obligations or liquidity events not detailed in this summary.